Knight Therapeutics Inc.

Good morning, ladies and gentlemen. My name is Chad, and I will be your operator today. Welcome to Knight Therapeutics, Inc. First Quarter 2022 Results Conference Call. Before turning the call over to Samira Sakia, President and CEO of Knight, listeners are reminded that portions of today's discussion may, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the floor-looking statements. The company considers the assumptions on which these forward-looking statements are based to be reasonable at the time that they were prepared, but cautious that these assumptions regarding the future events, many of which are beyond the control of the company and its subsidiaries, may ultimately prove to be incorrect. The company disclaims any intention or obligation to update or revise any forward-looking statements, whether a result of new information, future events, except as required by law. We would also like to remind you, questions during today's call will be taken from analysts only. Should there be any further questions, please contact Knight's Investor Relations Department by email at info at knighttx.com or via phone 514-484-4483. I would like to remind everyone that this call is being recorded today, May 12, 2022, and would now like to turn the meeting over to your host for today's call, Samara Sakia. Please go ahead, Ms. Sakia.

Thank you, Chad. Good morning, everyone, and welcome to Knight's Q122 conference call. I'm joined today on today's call with Amal Khoury, our Chief Business Officer, Arvind Uchina, our Chief Financial Officer, and Jeff Martins, our Global VP of Commercial. I'm excited to report that in the first quarter of 2022, Knight's revenues were $63.8 million, which represents an increase of $17.7 million, or 39% versus Q1 2021. In addition to the $7.1 million of contribution from Exelon, we had revenue growth across all our therapeutic areas driven by market penetration of our key promoter brands and an increase in patient treatments due to reduced COVID-19 restrictions. And on the business development front, we just announced that we entered into an exclusive license distribution and supply agreement with HealthSend for two products for Canada, Brazil, and select LATAM countries. Now that we have completed our organizational changes in the executive and senior management team, we are focused on continuing to leverage the platform and growing the business while finalizing the implementation of the ERP and the quality management systems and optimizing our manufacturing structure. We expect to complete the ERP implementation in all entities except the Argentinian affiliates by the end of 2022. Turning now to the NCIB. During the first quarter of 22, we purchased approximately 1.7 million common shares for an aggregate cash consideration of $9.1 million at an average price of $5.29 per share. Subsequent to the quarter, We purchased an additional 893,000 common shares for aggregate cash consideration of $4.8 million or $5.33 per share. I will now turn the call over to Jeff to provide more details on our product results.

Thank you, Samira. Building on our hard work of 2021, our efforts in 2022 remain focused on the executional excellence of our new product launches while delivering competitive growth for our mature promoted portfolio. In the quarter, we delivered growth across all therapeutic areas. In addition to Exelon, we had growth of $5.3 million in our oncology-hematology portfolio, which includes the contribution from launches of Lemvima, Alevin, and Rembray. As for our antifungals portfolio, you may recall that these products are used in patients who are immunocompromised, mostly post-treatment for oncology or hematology conditions. As these treatments resumed versus Q1 2021 lockdowns, there was a return to normal utilization of our antifungal products. Consequently, we saw an increase of $5.8 million in our infectious disease sales for Q1 2021. I will now turn the call over to Arvind to go over the financial results. Thank you, Jeff.